Financing channel feed – Endpoints News

Financing channel feed

Acesion clinches $47M in Series B raise to advance preclinical cardiac arrhythmia candidate through PhII

Last year

BridgeBio inks $250M PIPE two months after PhIII heart pill win, hints at more financing

Last year

Labcorp backs Adela’s $48M Series A1 to advance methylation-based head and neck cancer test

Last year

LB Pharmaceuticals raising $75M for schizophrenia drug as Karuna looks to change the field

Last year

After Versanis success, Aditum launches Celexor Bio with autoimmune drug from Acelyrin partner Inmagene

Last year

A new George Church startup raises $16M. The first-time founders have a ‘crazy vision’ to bring ML to cell therapy

Last year

Tolremo raises $39M Series A to advance drug designed to dismantle early cancer defenses

Last year

RNA editing startup launches with $30M based on Stanford and University of Tübingen research

Last year

With covalent meds abuzz, RA Capital and Novartis lead $56M seed round for new startup

Last year

Stuart Schreiber startup launches with $50M to take molecular glue medicines beyond protein degradation

Last year

Exclusive: Backed by former Google CEO’s VC, a Colorado biotech hatches platform to evolve degraders

Last year

CDMOs Nephron and Canton each raise hundreds of millions in financing

Last year

BioNTech nabs up to $90M for mpox vaccine as it begins PhI/II trial behind Moderna's lead

Last year

Exclusive: Backed by Illumina, Broken String Biosciences raises $15M to find off-target gene edits

Last year

Neumora, RayzeBio ride onto Nasdaq in IPO doubleheader, breathing life into fall listings

Last year

Flagship’s AI unicorn Generate raises $273M Series C, as first drug in 17-program pipeline enters the clinic

Last year

After an $80M Series D raise, DalCor takes another shot at a PhIII myocardial infarction trial

Last year

Rocket Pharmaceuticals says FDA agrees to 12-patient study for accelerated approval, expects to raise $175M

Last year

Exclusive: Pharmacy adherence startup Sempre Health raises $20M

Last year

Mironid reaches $43.7M to date in Series A extension to fund kidney disease treatment studies

Last year

Avalon's latest biotech closes $58M round as it pursues treatments for autoimmune brain conditions

Last year

Renibus brings Series B total to $72M, securing registrational development for lead heart surgery candidate

Last year

Rome Therapeutics advances dark genome drug after completing $72M Series B extension backed by Big Pharma

Last year

Actio locks in $55M Series A raise to advance rare disease pipeline based on human genetic platform

Last year

First page Previous page 26 27 282930 31 32 Next page Last page